PACS Group, Inc. (PACS) stock price is $47.98, up 0.54% on the day, as of Oct 21, 2026. It has a market cap of $7.55Bn and a P/E ratio of 28.03, and is classified in the Home Health and Senior Care industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap7.55 Bn
P/E28.03
P/S1.36
Div. Yield0.00
Total Debt (Qtr)246.09 Mn
Revenue Growth (1y) (Qtr)9.07
Add ratio to table…
About
PACS Group, Inc. is a leading post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities. The company provides senior care, assisted living, and independent living options in some of its communities. As of December 31, 2025, PACS Group operated 321 post-acute care facilities across 17 states, serving over 31,700 patients daily.
PACS Group generates revenue primarily from payments…
PACS Group, Inc. is a leading post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities. The company provides senior care, assisted living, and independent living options in some of its communities. As of December 31, 2025, PACS Group operated 321 post-acute care facilities across 17 states, serving over 31,700 patients daily.
PACS Group generates revenue primarily from payments by third-party payors, including Medicare and Medicaid, which accounted for 33.7% and 40.5% of routine revenue for the year ended December 31, 2025, respectively. The company also receives revenue from managed care, private pay, and other payor sources for skilled nursing and related services provided at its facilities.
The company operates through the following segments: Mature facilities, Ramping facilities, and New facilities.
Mature facilities are defined as facilities purchased more than 36 months prior to the measurement date. As of December 31, 2025, PACS Group operated 150 Mature facilities that generated $2.9 billion in skilled nursing services revenue for the year ended December 31, 2025, with an average QM Star rating of 4.4, an occupancy rate of 95%, and a skilled mix by revenue of 56%.
Ramping facilities are defined as facilities purchased within 18 to 36 months prior to the measurement date. As of December 31, 2025, PACS Group operated 102 Ramping facilities that generated $1.1 billion in skilled nursing services revenue for the year ended December 31, 2025, with an average QM Star rating of 4.1, an occupancy rate of 86%, and a skilled mix by revenue of 42%.
New facilities are defined as facilities purchased less than 18 months prior to the measurement date. As of December 31, 2025, PACS Group operated 69 New facilities that generated $1.2 billion in skilled nursing services revenue for the year ended December 31, 2025, with an average QM Star rating of 3.5, an occupancy rate of 81%, and a skilled mix by revenue of 38%.
PACS Group is one of the largest skilled nursing facility operators in the United States based on the number of facilities, as reported by CMS. The company differentiates itself through its locally led, centrally supported operating model, which empowers local facility administrators to make autonomous clinical and operational decisions while providing centralized support via PACS Services. PACS Group’s competitive strengths include superior clinical quality reflected in above-industry average QM Star ratings and occupancy rates, a meritocratic leadership culture, a robust suite of technology-enabled services, and a disciplined acquisition playbook focused on transforming underperforming facilities into higher-value short-term transitional care centers.
PACS Group serves patients requiring post-acute care, including individuals recovering from surgery, strokes, joint replacements, and acute infections who need 24-hour inpatient services after hospital discharge. The company’s primary patient demographic consists of adults aged 65 and older, with a focus on higher acuity, short-term transitional care patients. The company also works with referring providers such as hospitals and health systems, payors including Medicare and Medicaid, and interdisciplinary clinical teams at each facility.
Sector:HealthcareSector rationalePACS Group operates post-acute healthcare facilities, providing skilled nursing, assisted living, and independent living services to patients. Its revenue is derived from providing medical care and inpatient services paid for by Medicare, Medicaid, and private payors, which aligns directly with the Healthcare sector's 'Home Health and Senior Care' and 'Healthcare Services' industries.Industry:Home Health and Senior CareHome Health and Senior CarePrimaryPACS Group operates 321 post-acute care facilities providing skilled nursing care, assisted living, and independent living options. Its revenue is derived from Medicare, Medicaid, and private pay for services delivered in these residential settings.Classified using BQ-MICSCIK: 0002001184
Bull & bear
Investment Thesis
▲ Bull case
PACS's operational platform demonstrates consistent organic growth through its facility maturation lifecycle, with ramping facilities showing accelerating progression toward mature performance levels and internal improvements driving strong performance without reliance on external growth, as evidenced by the ramping cohort averaging 88.9% occupancy with improving skilled mix and new facilities at 82.7% occupancy with 26.5% skilled mix reflecting early-stage integration progress toward mature benchmarks, positioning the company to capture predictable, repeatable growth from its existing portfolio as facilities advance through defined integration stages, reducing dependence on acquisition-driven growth and enhancing earnings stability through internally generated operational discipline and clinical execution improvements across cohorts.
The company's strategic focus on quality-driven reimbursement programs, such as California's WQIP and emerging opportunities in Ohio and Texas, provides a significant yet underappreciated catalyst for margin expansion, with PACS earning approximately $16.3 million in net EBITDA benefit from WQIP in Q1 FY26 alone and anticipating two additional 2025 program year payments in 2026, while management actively advocates for successor programs and highlights its ability to outperform in quality-based initiatives due to its high clinical standards, evidenced by 222 facilities rated 4 or 5 stars under CMS (up from 207) and a mature facility average star rating of 4.4 versus the industry average of 3.6, creating a structural advantage where superior operational performance directly translates to incremental, sustainable revenue streams not fully captured in current guidance due to the exclusion of unpredictable quality incentive payments.
PACS maintains a fortress-like balance sheet with net leverage of just 0.1 times, approximately $800 million in available liquidity ($250 million cash), and a conservative capital structure that enables disciplined pursuit of both organic growth initiatives and selective acquisitions, supported by a $600 million line of credit with only $45 million drawn and a newly authorized $250 million share repurchase program that allows opportunistic capital return when shares are undervalued, providing downside protection and flexibility to enhance shareholder value through multiple channels without compromising growth investments or financial stability, a combination rarely seen in the fragmented skilled nursing sector where peers often face constraining leverage or limited liquidity.
The company's localized scale strategy, emphasizing density in key markets to leverage local leadership, clinical resources, and referral relationships, is creating a self-reinforcing competitive moat that improves operational consistency and long-term growth potential, as facility leaders empowered to make point-of-care decisions are supported by PAC Services' infrastructure and systems, enabling strong, repeatable results even during scaling, a model validated by the successful turnaround of a previously challenged Arizona facility acquired in 2023 that graduated from special focus status after cultural and systemic improvements, demonstrating the platform's ability to identify operational opportunities, install strong local leadership, and drive measurable, sustainable improvement over time—a capability that is difficult for fragmented competitors to replicate at scale.
PACS's operational platform demonstrates consistent organic growth through its facility maturation lifecycle, with ramping facilities showing accelerating progression toward mature performance levels and internal improvements driving strong performance without reliance on external growth, as evidenced by the ramping cohort averaging 88.9% occupancy with improving skilled mix and new facilities at 82.7% occupancy with 26.5% skilled mix reflecting early-stage integration progress toward mature benchmarks, positioning the company to capture predictable, repeatable growth from its existing portfolio as facilities advance through defined integration stages, reducing dependence on acquisition-driven growth and enhancing earnings stability through internally generated operational discipline and clinical execution improvements across cohorts.
The company's strategic focus on quality-driven reimbursement programs, such as California's WQIP and emerging opportunities in Ohio and Texas, provides a significant yet underappreciated catalyst for margin expansion, with PACS earning approximately $16.3 million in net EBITDA benefit from WQIP in Q1 FY26 alone and anticipating two additional 2025 program year payments in 2026, while management actively advocates for successor programs and highlights its ability to outperform in quality-based initiatives due to its high clinical standards, evidenced by 222 facilities rated 4 or 5 stars under CMS (up from 207) and a mature facility average star rating of 4.4 versus the industry average of 3.6, creating a structural advantage where superior operational performance directly translates to incremental, sustainable revenue streams not fully captured in current guidance due to the exclusion of unpredictable quality incentive payments.
PACS maintains a fortress-like balance sheet with net leverage of just 0.1 times, approximately $800 million in available liquidity ($250 million cash), and a conservative capital structure that enables disciplined pursuit of both organic growth initiatives and selective acquisitions, supported by a $600 million line of credit with only $45 million drawn and a newly authorized $250 million share repurchase program that allows opportunistic capital return when shares are undervalued, providing downside protection and flexibility to enhance shareholder value through multiple channels without compromising growth investments or financial stability, a combination rarely seen in the fragmented skilled nursing sector where peers often face constraining leverage or limited liquidity.
The company's localized scale strategy, emphasizing density in key markets to leverage local leadership, clinical resources, and referral relationships, is creating a self-reinforcing competitive moat that improves operational consistency and long-term growth potential, as facility leaders empowered to make point-of-care decisions are supported by PAC Services' infrastructure and systems, enabling strong, repeatable results even during scaling, a model validated by the successful turnaround of a previously challenged Arizona facility acquired in 2023 that graduated from special focus status after cultural and systemic improvements, demonstrating the platform's ability to identify operational opportunities, install strong local leadership, and drive measurable, sustainable improvement over time—a capability that is difficult for fragmented competitors to replicate at scale.
PACS's reliance on unpredictable, non-recurring quality incentive payments creates material risk to earnings sustainability, as the company explicitly excludes these payments from guidance due to timing and amount uncertainty, yet benefited from approximately $16.3 million in net EBITDA from California's WQIP in Q1 FY26—a program discontinued after 2024 with only residual 2025 program year payments expected, and while management cites potential successor programs in California and opportunities in Ohio and Texas, there is no assurance these will materialize at comparable levels, leaving the company vulnerable to earnings volatility if such programs are not renewed or replaced, particularly given that even excluding WQIP, adjusted EBITDA growth was $57 million year-over-year in Q1 FY26, suggesting the core business may not be generating sufficient organic margin expansion to offset the loss of these transient benefits.
The skilled nursing industry faces mounting structural cost pressures from unfunded mandates, exemplified by California's healthcare staffing minimum wage increases, which directly impact SNFs through non-funded labor cost increases that management acknowledged would affect pricing competitiveness against hospitals and health systems, yet the company provided no concrete mitigation strategy beyond noting positive labor trends and union relationships, leaving exposure to rising wage-related expenses that could compress margins if reimbursement rates fail to keep pace, especially in high-cost states like California where labor constitutes a significant portion of operating costs and the company's optimism about labor environment may not translate to effective cost control amid industry-wide staffing challenges.
PACS's growth strategy remains heavily dependent on successful facility integration and progression through the ramping-to-mature lifecycle, yet the company disclosed that new facilities averaged only 82.7% occupancy with 26.5% skilled mix—meaningfully below mature facility benchmarks of 94.8% occupancy and 33% skilled mix—indicating a prolonged stabilization period that delays profit contribution, and while management views this as internally driven improvement, the slow ramp-up in newer geographic markets entered during the 2024 expansion increases execution risk, particularly if local market dynamics, referral patterns, or competitive pressures hinder the expected trajectory toward mature performance levels, potentially resulting in prolonged suboptimal returns on recent investments.
Despite a strong balance sheet and liquidity position, PACS's capital allocation priorities introduce uncertainty, as the $250 million share repurchase authorization—while flexible—could divert capital from acquisitions or operational investments if deployed opportunistically, and management's acknowledgment of evaluating larger portfolio acquisitions with more immediate EBITDA impact suggests a potential shift toward transformative M&A that may face integration challenges, regulatory scrutiny, or overpayment risks in a fragmented industry, yet the company provided no clear framework for how it will balance buybacks, dividends, debt reduction, and growth investments, creating ambiguity about long-term value creation strategy amid competing uses of strong cash flow generation.
PACS's reliance on unpredictable, non-recurring quality incentive payments creates material risk to earnings sustainability, as the company explicitly excludes these payments from guidance due to timing and amount uncertainty, yet benefited from approximately $16.3 million in net EBITDA from California's WQIP in Q1 FY26—a program discontinued after 2024 with only residual 2025 program year payments expected, and while management cites potential successor programs in California and opportunities in Ohio and Texas, there is no assurance these will materialize at comparable levels, leaving the company vulnerable to earnings volatility if such programs are not renewed or replaced, particularly given that even excluding WQIP, adjusted EBITDA growth was $57 million year-over-year in Q1 FY26, suggesting the core business may not be generating sufficient organic margin expansion to offset the loss of these transient benefits.
The skilled nursing industry faces mounting structural cost pressures from unfunded mandates, exemplified by California's healthcare staffing minimum wage increases, which directly impact SNFs through non-funded labor cost increases that management acknowledged would affect pricing competitiveness against hospitals and health systems, yet the company provided no concrete mitigation strategy beyond noting positive labor trends and union relationships, leaving exposure to rising wage-related expenses that could compress margins if reimbursement rates fail to keep pace, especially in high-cost states like California where labor constitutes a significant portion of operating costs and the company's optimism about labor environment may not translate to effective cost control amid industry-wide staffing challenges.
PACS's growth strategy remains heavily dependent on successful facility integration and progression through the ramping-to-mature lifecycle, yet the company disclosed that new facilities averaged only 82.7% occupancy with 26.5% skilled mix—meaningfully below mature facility benchmarks of 94.8% occupancy and 33% skilled mix—indicating a prolonged stabilization period that delays profit contribution, and while management views this as internally driven improvement, the slow ramp-up in newer geographic markets entered during the 2024 expansion increases execution risk, particularly if local market dynamics, referral patterns, or competitive pressures hinder the expected trajectory toward mature performance levels, potentially resulting in prolonged suboptimal returns on recent investments.
Despite a strong balance sheet and liquidity position, PACS's capital allocation priorities introduce uncertainty, as the $250 million share repurchase authorization—while flexible—could divert capital from acquisitions or operational investments if deployed opportunistically, and management's acknowledgment of evaluating larger portfolio acquisitions with more immediate EBITDA impact suggests a potential shift toward transformative M&A that may face integration challenges, regulatory scrutiny, or overpayment risks in a fragmented industry, yet the company provided no clear framework for how it will balance buybacks, dividends, debt reduction, and growth investments, creating ambiguity about long-term value creation strategy amid competing uses of strong cash flow generation.